Las Vegas NV 心血管疾病临床试验
6项针对 心血管疾病的研究正在 Las Vegas及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本(英文)
正在为研究招募参与者?将此页面置顶展示 — $99 / 30天 →
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
招募中2 期
- Excel Clinical Research, LLC, Las Vegas
- Palm Research Center Tenaya, Las Vegas
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
招募中3 期
- Las Vegas Clinical Trials, Las Vegas
- AB Clinical Trials, Las Vegas
- Palm Research Center, Las Vegas
- 以及另外 2 项
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
招募中3 期
- Vector Clinical Trials, Las Vegas
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
招募中3 期
- Clinical Trial Site, Las Vegas
- Clinical Trial Site, Las Vegas
- Clinical Trial Site, Las Vegas
- 以及另外 1 项
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
招募中3 期
- Research Site, Las Vegas
- Research Site, Las Vegas
- Research Site, Las Vegas
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
招募中3 期
- Excel Clinical Research, Las Vegas
- American Institute of Medical Research, Las Vegas
其他城市的 心血管疾病试验
- Boston, MA37 项研究
- New York City, NY33 项研究
- Washington, DC28 项研究
- Houston, TX24 项研究
- Dallas, TX23 项研究
- Atlanta, GA22 项研究
- Cleveland, OH22 项研究
- Chicago, IL21 项研究
- Philadelphia, PA21 项研究
- Pittsburgh, PA20 项研究
- St. Louis, MO20 项研究
- Nashville, TN18 项研究
Las Vegas的其他研究
- 肥胖症27 项研究
- 超重23 项研究
- 2型糖尿病18 项研究
- 非小细胞肺癌13 项研究
- 重度抑郁症13 项研究
- 乳腺癌10 项研究
- 阿尔茨海默病8 项研究
- 急性髓系白血病8 项研究
- 前列腺癌8 项研究
- 癌症(所有类型)8 项研究
- 精神分裂症7 项研究
- 动脉粥样硬化7 项研究
数据来自 ClinicalTrials.gov,检索日期:2026年10月6日。每项研究自行设定入选标准,由研究团队决定谁能参与。